Cizza G, et al. “Depression: A Major, Unrecognized Risk Factor for Osteoporosis?” Trends in Endocrinology and Metabolism (July 2001): Vol. 12, No. 5, pp. 198–203. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11397644

Cizza G, et al. “Elevated Neuroimmune Biomarkers in Sweat Patches and Plasma of Premenopausal Women with Major Depressive Disorder in Remission: The POWER Study,” Biological Psychiatry (Nov. 15, 2008): Vol. 64, No. 10, pp. 907–11. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18657799

Diem SJ, et al. “Use of Antidepressants and Rates of Hip Bone Loss in Older Women: The Study of Osteoporotic Fractures,” Archives of Internal Medicine (June 25, 2007): Vol. 167, No. 12, pp. 1240–45. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17592096

Eskandari F, et al. “Low Bone Mass in Premenopausal Women with Depression,” Archives of Internal Medicine (Nov. 26, 2007): Vol. 167, No. 21, pp. 2329–36. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18039992

Haney EM, et al. “Association of Low Bone Mineral Density with Selective Serotonin Reuptake Inhibitor Use by Older Men,” Archives of Internal Medicine (June 25, 2007): Vol. 167, No. 12, pp. 1246–51. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17592097

Haney EM, et al. “Skeletal Effects of Serotonin (5-Hydroxytryptamine) Transporter Inhibition: Evidence from Clinical Studies,” Journal of Musculoskeletal and Neuronal Interactions (April–June 2008): Vol. 8, No. 2, pp. 133–45. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18622082

Michelson D, et al. “Bone Mineral Density in Women with Depression,” New England Journal of Medicine (Oct. 17, 1996): Vol. 335, No. 16, pp. 1176–81. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8815939

Richards JB, et al. “Effect of Selective Serotonin Reuptake Inhibitors on the Risk of Fracture,” Archives of Internal Medicine (Jan. 22, 2007): Vol. 167, No. 2, pp. 188–94. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17242321

Rosen CJ. “Bone Remodeling, Energy Metabolism, and the Molecular Clock,” Cell Metabolism (Jan. 2008): Vol. 7, No. 1, pp. 7–10. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18177720

Rosen CJ. “Serotonin Rising—The Bone, Brain, Bowel Connection,” New England Journal of Medicine (March 5, 2009): Vol. 360, No. 10, pp. 957–59. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19264685

Spangler L, et al. “Depressive Symptoms, Bone Loss, and Fractures in Postmenopausal Women,” Journal of General Internal Medicine (May 2008): Vol. 23, No. 5, pp. 567–74. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18286345

Tam J, et al. “The Cannabinoid CB1 Receptor Regulates Bone Formation by Modulating Adrenergic Signaling,” FASEB Journal (Jan. 2008): Vol. 22, No. 1, pp. 285–94. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17704191

Warden SJ, et al. “Serotonin (5-Hydroxytryptamine) Transporter Inhibition Causes Bone Loss in Adult Mice Independently of Estrogen Deficiency,” Menopause (Nov.–Dec. 2008): Vol. 15, No. 6, pp. 1176–83. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18725867

Williams LJ, et al. “Selective Serotonin Reuptake Inhibitor Use and Bone Mineral Density in Women with a History of Depression,” International Clinical Psychopharmacology (March 2008): Vol. 23, No. 2, pp. 84–87. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18301122

Yadav VK, et al. “Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum,” Cell (Nov. 28, 2008): Vol. 135, No. 5, pp. 825–37. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19041748